KCNQ1 Variant Map Links Channel Function to Long QT Syndrome

Key Takeaways

• Among protein-coding KCNQ1 variants studied in pooled laboratory assays, some showed strong pathogenic functional evidence while others showed moderate benign functional evidence.
• Loss-of-function variants were significantly associated with QT prolongation and long QT syndrome in case–control and biobank analyses.
• Dominant-negative effects occurred in a majority of variants described as pathogenic, and this functional group was associated with more arrhythmia diagnoses than haploinsufficient variants.

A KCNQ1 variant of uncertain significance can leave its relationship to congenital long QT syndrome unresolved. As genetic testing identifies more such variants, clinical interpretation and risk stratification become harder when their effects on cell-surface abundance and ion-channel function are unknown. A variant may also behave differently alongside an unaltered copy of the gene than in a variant-only setting. Measuring function in both biological settings can help characterize that uncertainty.

Investigators in the Circulation study of KCNQ1 variant effects assembled a nearly comprehensive library of protein-coding variants. Four pooled assays followed by high-throughput sequencing measured cell-surface abundance and channel function in variant-only and heterozygous states. The investigators used case–control analyses and large-scale biobank data to assess associations of loss-of-function variants with QT prolongation and long QT syndrome. They also used heterozygous results to assess dominant-negative effects, compared arrhythmia diagnoses between dominant-negative and haploinsufficient functional groups, and examined whether deleterious variant classes clustered within protein structure.

The assays produced 49,305 functional measurements across 13,403 protein-coding KCNQ1 variants. These measurements characterized cellular abundance and channel behavior; separate observational analyses assessed clinical associations. Loss-of-function variants were significantly associated with QT prolongation and long QT syndrome in the case–control and biobank analyses.

Functional mapping assigned strong pathogenic evidence to 1,757 variants and moderate benign evidence to 6,660 variants. These categories describe functional evidence from the assays. A majority of variants described as pathogenic exhibited dominant-negative effects. Compared with haploinsufficient variants, the dominant-negative group was associated with a higher risk of arrhythmia diagnoses. The reported comparison concerned diagnoses rather than confirmed arrhythmic events.

Laboratory assays characterize KCNQ1 variants under measured conditions, whereas case–control and biobank analyses associate functional groups with clinical observations. Neither assay behavior nor observational diagnoses establish an individual carrier’s arrhythmia risk or demonstrate a benefit from changing treatment.

According to the investigators, the functional atlas supplies evidence for most KCNQ1 variants of uncertain significance and links genetic variation with ion-channel biology and arrhythmia susceptibility.

Clinician Questions

Does strong pathogenic evidence from KCNQ1 functional mapping confirm a patient's variant causes long QT syndrome?

For congenital long QT syndrome, KCNQ1 assay categories indicate strong pathogenic or moderate benign functional evidence, not independently confirmed clinical pathogenicity or benignity for an individual patient’s variant. The assay result alone does not establish that the variant causes the condition.

Do damaging KCNQ1 variants cluster in different regions of the ion-channel protein?

In KCNQ1 variant-effect mapping, deleterious variants clustered in distinct structural domains according to functional classification. This observed pattern relates to KCNQ1 ion-channel biology in congenital long QT syndrome; protein position alone does not establish an individual’s diagnosis or arrhythmia risk.